Accelerating Access to Lenacapavir: Everyone has a role to play

This year, the HIV prevention community witnessed a landmark moment with the results of the lenacapavir (LEN) for PrEP PURPOSE 1 and 2 trials, which showed nearly complete protection against HIV. Named as “breakthrough of the year” by Science Magazine, LEN’s every-six-month injectable dosing has the potential to transform the HIV response, but only if it is rolled out with speed, scale and equity. Gilead Sciences, the developer of LEN, has repeatedly stated that they will begin submitting applications to national regulatory agencies to market LEN for PrEP before the end of the year. WHO is also beginning to develop guidelines for LEN for PrEP. And just this week, PEPFAR and the Global Fund announced a coordinated effort to reach two million people with access to LEN. So, the clock is ticking and achieving this vision – and significantly reduce global HIV infections requires coordination at every level. 

We released a new framework, the Gears of LEN for PrEP Rollout, which provides more details about all the moving parts needed to accelerate equitable access – and the necessary lubrication to ensure the world does not squander this opportunity. Read a new op-ed penned by Jirair Ratevosian and Mitchell Warren in Devex describing this process and read more below about this framework and tools and strategies to support the advocacy needed.